Oskarsdottir Gudrun N, Lampa Erik, Berglund Anders, Rosengren Linda, Ulvestad Maria, Boros Miklos, Daumont Melinda J, Rault Caroline, Emanuel Gabrielle, Leal Cátia, Schoemaker Minouk J, Wagenius Gunnar
Department of Respiratory Medicine and Allergology, Skåne University Hospital, V/O Hjärt- och Lungmedicin, 222 42 Lund, Sweden.
Division of Oncology, Department of Clinical Sciences Lund, Lund University, Medicon Village, 22 381 Lund, Sweden.
Cancers (Basel). 2024 Apr 25;16(9):1655. doi: 10.3390/cancers16091655.
Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, with ~40-50% of patients diagnosed with non-metastatic disease (stages IA-IIIC). The treatment landscape is evolving rapidly as immunotherapies and targeted therapy are introduced in the non-metastatic setting, creating a need to assess patient outcomes prior to their introduction. This real-world study using Swedish National Lung Cancer Registry data examined outcomes (overall survival (OS) and time to next treatment or death (TTNTD)) and treatment patterns for adults diagnosed with non-metastatic NSCLC. Baseline characteristics and OS from diagnosis were described for all patients; OS, treatment patterns, and TTNTD from treatment start were described for the treatment subgroup (patients diagnosed from 2014 onwards), stratified by disease stage and initial treatment. OS and TTNTD were described using the Kaplan-Meier estimator. The overall population (2008-2019) included 17,433 patients; the treatment subgroup included 5147 patients. Median OS (interquartile range) overall ranged from 83.3 (31.6-165.3) months (stage I patients) to 10.4 (4.3-24.2) months (stage IIIB patients). Among the treatment subgroup, median OS and TTNTD were longest among patients receiving surgery versus other anticancer treatments. These findings provide a baseline upon which to evaluate the epidemiology of non-metastatic NSCLC as newer treatments are introduced.
非小细胞肺癌（NSCLC）是全球癌症相关死亡的主要原因，约40-50%的患者被诊断为非转移性疾病（IA-IIIC期）。随着免疫疗法和靶向疗法在非转移性疾病治疗中的引入，治疗格局正在迅速演变，因此需要在这些疗法引入之前评估患者的预后。这项基于瑞典国家肺癌登记数据的真实世界研究，考察了被诊断为非转移性NSCLC的成年人的预后（总生存期（OS）和至下次治疗或死亡时间（TTNTD））及治疗模式。描述了所有患者的基线特征和自诊断起的OS；按疾病分期和初始治疗分层，描述了治疗亚组（2014年起诊断的患者）自治疗开始起的OS、治疗模式和TTNTD。使用Kaplan-Meier估计量描述OS和TTNTD。总体人群（2008-2019年）包括17433例患者；治疗亚组包括5147例患者。总体中位OS（四分位间距）范围从83.3（31.6-165.3）个月（I期患者）到10.4（4.3-24.2）个月（IIIB期患者）。在治疗亚组中，接受手术治疗的患者的中位OS和TTNTD比接受其他抗癌治疗的患者更长。随着新疗法的引入，这些发现为评估非转移性NSCLC的流行病学提供了一个基线。
